Medical News

RSS

Color of skin impacts health, say researchers

Researchers from the universities of Bristol and St. Andrews in the UK have found that the color of a person's skin affects how healthy and therefore attractive they appear, and have found that diet may be crucial to achieving the most desirable complexion. The work will be published in the December issue of Springer's International Journal of Primatology.

16 Nov 2009

China Medicine reports total revenues of $19.2M for the third quarter of 2009

China Medicine Corporation, a developer and a leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations, today announced its third quarter 2009 results.

16 Nov 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.

16 Nov 2009

Preliminary fourth-quarter 2009 financial results from Winner Medical

Winner Medical Group Inc., today reported preliminary financial results for the fourth quarter 2009. The unaudited numbers are subject to change.

16 Nov 2009

Cambridge Heart announces financial results for the third quarter of 2009

Cambridge Heart, Inc., today reported results for its third quarter ended September 30, 2009. The following financial and strategic items highlight the Company’s activity for the third quarter.

16 Nov 2009

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $3,243,000, or $0.06 per share for the quarter ended September 30, 2009 compared with a net loss applicable to common stock of $3,148,000, or $0.07 per share for the corresponding prior year period.

16 Nov 2009

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009

HIRC recognizes CDPHP for offering best disease management program in upstate New York

Health Dialog Services Corporation, a leading provider of healthcare decision programs, today announced that its client, Capital District Physicians’ Health Plan, Inc. (CDPHP®), has been recognized by the Health Industries Research Cos. (HIRC) for offering the best disease management program in upstate New York.

16 Nov 2009

First-quarter fiscal 2010 results announced by IsoRay

IsoRay Inc. a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the first quarter of fiscal year 2010, ended September 30, 2009.

16 Nov 2009

Bright Now! Dental announces the opening of Castle Dental office in Kyle

Bright Now! Dental Inc., the nation’s leading provider of business support services to dentists, announces the grand opening of a new Castle Dental office in Kyle. Located at 5103 Kyle Center Drive in the Kyle Corners Shopping Center, the office provides families with a convenient, comfortable environment where they can receive the latest in comprehensive, full-serve quality dental care.

16 Nov 2009

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

PGxHealth, a division of Clinical Data, Inc., today announced the launch of its genetic test for familial Dilated Cardiomyopathy, an inherited heart disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death.

16 Nov 2009

Windhover Information selects Oncothyreon's PX-866 among top 10 oncology projects for partnering

Oncothyreon Inc. today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering.

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Advanced Cell Technology to raise funds through private placements

Advanced Cell Technology, Inc., announced today that it has entered into definitive agreements on three private placements with institutional and other accredited investors under which the Company has received definitive commitments in excess of $15 million.

16 Nov 2009

Positive results from Winston Laboratories' Civamide Patch trial

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced positive top-line results from Study WL1001-04-03, a Phase II clinical trial evaluating the safety and efficacy of the company's patch formulation of Civamide, a novel TRPV-1 receptor modulator in the treatment of post-herpetic neuralgia (PHN).

16 Nov 2009

Neighborhood Healthcare selects eClinicalWorks EMR and PM solution

eClinicalWorks®, a market leader in ambulatory clinical systems, today announced that Neighborhood Healthcare, which serves Riverside and San Diego counties, has selected eClinicalWorks unified electronic medical records (EMR) and practice management (PM) solution along with eClinicalWorks Enterprise Business Optimizer’s (eBO) enhanced reporting capabilities for its 115 providers across 11 locations.

16 Nov 2009

CCSA to focus on role of treatment systems at Canada's Issues of Substance 2009 conference

The Canadian Centre on Substance Abuse (CCSA) today announced that it will open Issues of Substance (IOS) 2009, Canada's biennial conference on substance abuse, with a focus on the role of treatment systems. More than 13 sessions will examine the role of treatment from a variety of perspectives, including the Models of Care project in the UK, the National Treatment Strategy in Canada (NTS) and case study and research presentations reviewing the effectiveness of a variety of integrated programs in Canada.

16 Nov 2009

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Three platelet function tests all identified heart patients who will have blood cells that remain sticky, increasing heart attack risk, despite being pre-treated with two anti-clotting medications before coronary stenting, researchers reported at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Myeloma UK launches innovative clinical trial network

Yorkshire myeloma patients are set to be among the first to benefit from an innovative Myeloma Clinical Trial Network launched by Myeloma UK.

16 Nov 2009

Alcohol mixed with energy drinks: Higher prevalence of sexual assault and injury in college students

Emergency physician Mary Claire O'Brien, M.D., of Wake Forest University Baptist Medical Center, has done extensive research on the risks and dangers of alcoholic energy drinks (AEDs).

16 Nov 2009